Clinical trial NCT01907373: Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers
Official title: Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Drug Interaction of Olmesartan in Healthy Chinese Volunteers
Keywords: olmesartan
probenecid
pharmacokinetics
tolerability
Lead sponsor: Central South University
Sponsor class: OTHER
First posted: 2013-07-25
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Hypertension and hyperuricaemia are widespread conditions. There is significant overlap between the two conditions. Serum uric acid (SUA) is currently recognized as a risk factor for cardiovascular disease. Thus, at some point in their therapy, hypertensive patients with hyperuricaemia are likely to require concurrent treatment with anti-hypertensive and hypouricaemic agents. For this reason, it is important to determine whether there are any pharmacokinetic interactions resulting from the concomitant administration of such agents.Olmesartan is an angiotensin II receptor antagonist and effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricaemic agent for the treatment of hyperuricaemia and gout.The goal of this study was to examine the impact of coadministration of probenecid on the pharmacokinetic parameters and tolerability of olmesartan in healthy volunteers.

Detailed description: Probenecid is a well-established hypouricaemic agent for the treatment of hyperuricaemia and gout and is thought to act on urate transporter 1 (URAT1), a novel member of the organic anion transporter (OAT) family, thereby increasing uric acid excretion in the kidney by blocking urate reuptake, and then, resulting in a decrease of SUA.

Olmesartan is an angiotensin II receptor antagonist and effective and well tolerated in the treatment of arterial hypertension. Olmesartan is orally administered in the prodrug form, olmesartan medoxomil, which is converted to the pharmacologically-active compound olmesartan upon de-esterification by the enzyme arylesterase in the intestinal wall, portal blood, and liver. Olmesartan is excreted by hepatobiliary and renal systems without further metabolism, and its pharmacokinetic profile is not affected by age or gender. In addition, the pharmacokinetic and pharmacodynamic profile of olmesartan is favorable, both in terms of providing effective 24-hour blood pressure (BP) control with once-daily dosing, and in restricting the likelihood of pharmacokinetic interactions with other drugs. Studies in vitro show organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, multidrug resistance-associated protein 2 (MRP 2), and breast cancer resistance protein (BCRP) are involved in hepatobiliary and renal transport of olmesartan. We know probenecid interferes with the kidneys' organic anion transporter (OAT). Will probenecid have effects on the pharmacokinetics of olmesartan thereby result in changes of antihypertensive effect and side effects of olmesartan? Until now, many clinical studies have shown olmesartan has no pharmacokinetic interactions with other drugs; moreover, there is no research about the interactions between olmesartan and probenecid. In this study, we assess the involvement of probenecid in the pharmacokinetics and tolerability of olmesartan.

Eligibility criteria: Inclusion Criteria:

* written informed consent obtained,
* age 18 to 40 years and a body mass index between 19 and 25 kg/m2;
* negative test results for HIV and hepatitis В and C non-smoking status and
* an unremarkable clinical history

Exclusion Criteria:

* has history or evidence of a renal, gastrointestinal, hepatic, or hematologic abnormality or
* any acute or chronic disease, or
* an allergy to any drugs

Primary outcomes:
measure: pharmacokinetic parameters
timeFrame: 48 hours after last administration of olmesartan medoxomil
Secondary outcomes:
measure: vital signs
timeFrame: at baseline (0) and at 1, 2, 3, 6, 12, 36, and 48 hours after last dosage of olmesartan medoxomil administration
Other outcomes:
measure: Laboratory tests
timeFrame: at baseline and after completion of the study during 48 hours
measure: electrocardiography
timeFrame: at baseline and after completion of the study during 48 hours
Locations:
city: Changsha
country: China
facility: Center of New Drug Clinical Trial, Hunan Provincial Tumor Hospital (The Affiliated Tumor Hospital of Xiangya Medical School of Central South University)
state: Hunan
Study officials:
affiliation: Center of New Drug Clinical Trial, Hunan Provincial Tumor Hospital (The Affiliated Tumor Hospital of Xiangya Medical School of Central South University)
name: Kunyan Li, phD
role: PRINCIPAL_INVESTIGATOR
affiliation: Center of New Drug Clinical Trial, Hunan Provincial Tumor Hospital (The Affiliated Tumor Hospital of Xiangya Medical School of Central South University)
name: Nong Yang, MS
role: STUDY_DIRECTOR
References:
citation: Li KY, Qiu Y, Jiang Y, Luo CH, Lin XP, Wang J, Yang N. Effect of probenecid on pharmacokinetics and tolerability of olmesartan in healthy chinese volunteers. Curr Ther Res Clin Exp. 2014 Jan 9;76:7-10. doi: 10.1016/j.curtheres.2013.11.004. eCollection 2014 Dec.